(Q79150759)

English

Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

scientific article published on October 15, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study (English)

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

phase III clinical trial

1 reference

based on heuristic

inferred from title

0 references

endometrial carcinoma

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

author name string

Michael Cibull

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Gary Reid

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Willie Andersen

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Gynecologic Oncology Group Study

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Holly H. Gallion

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14551299

20 March 2024

Virginia L. Brunetto

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14551299

20 March 2024

Samuel S. Lentz

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14551299

20 March 2024

John T. Soper

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14551299

20 March 2024

Robert A. Burger

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14551299

20 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14551299

20 March 2024

publication date

1 October 2003

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

15 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14551299

20 March 2024

full work available at URL

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2003.10.083

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Journal of Clinical Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

3808-3813

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14551299%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

Cancer statistics, 2001

1

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study

3

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

5

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study

6

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.

7

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

8

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group

9

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study

10

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium

11

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

12

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

13

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

15

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Circadian rhythms and cancer chemotherapy

18

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Circadian rhythms and cancer chemotherapy

19

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes

20

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group.

21

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Circadian rhythms and cancer chemotherapy

22

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation

24

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

A two-stage design for randomized trials with binary outcomes.

25

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Nonparametric Estimation from Incomplete Observations

28

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Regression Models and Life-Tables (with discussion)

29

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Use of Ranks in One-Criterion Variance Analysis

30

1 reference

10.1200/JCO.2003.10.083

https://api.crossref.org/works/10.1200/JCO.2003.10.083

20 March 2024

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q79150759&oldid=2106756275"